Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
BMO Capital Reiterates Outperform on Bristol-Myers Squibb (BMY)
January 25, 2019 8:45 AM ESTBMO Capital analyst, Alex Arfaei, reiterated an Outperform rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) following the company's 4Q earnings report. Arfaei remains comfortable with Bristol's independent business: from 2018 to 2022, BMO Capital forecasts revenue and EPS CAGRs of 5% and 8%,... More
